Patents Examined by Lynn A. Bristol
  • Biological materials and uses thereof
    Patent number: 11202837
    Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: December 21, 2021
    Assignee: ANTIKOR BIOPHARMA LIMITED
    Inventors: Mahendra Persaud Deonarain, Gokhan Yahioglu, Ioanna Stamati, Savvas Saouros, Prashant Bhimrao Kapadnis
  • Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
    Patent number: 11202829
    Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: December 21, 2021
    Assignee: NeoTX Therapeutics Ltd.
    Inventors: Asher Nathan, Michal Shahar
  • Antigen binding constructs to target molecules
    Patent number: 11203639
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 21, 2021
    Assignee: IMAGINAB, INC.
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Anti-cancer combination therapy
    Patent number: 11198726
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: December 14, 2021
    Assignee: Boerhinger Ingelheim International GmbH
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • Allogeneic tumor cell vaccine
    Patent number: 11185586
    Abstract: The described invention provides allogeneic tumor cell vaccines comprising tumor cell lines or tumor cell line variants that are genetically engineered to express a core group of three immunomodulatory molecules, and optionally additional R immunomodulatory polypeptides for induction of one or more subpopulations of PBMCs to proliferate in response to the expressed immunomodulatory molecules and to then enter an effector phase for killing of tumor cells. According to some embodiments, the tumor cell vaccine candidate can induce an immune response in the recipient cancer patient that cross reacts with the patient's own (autologous) tumor cells, the effects of which are sufficient to result in enhanced anti-tumor immunity contributing to the increased survival of a vaccinated patient cohort compared to a matched unvaccinated patient cohort.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: November 30, 2021
    Assignee: ALLOPLEX BIOTHERAPEUTICS, INC.
    Inventor: Frank Borriello
  • Anti-neuropilin antigen-binding proteins and methods of use thereof
    Patent number: 11186644
    Abstract: Provided herein are antibodies, or antigen binding fragments thereof, that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the antibodies, or antigen binding fragments thereof. Also provided are methods of using the antibodies, or antigen binding fragments thereof, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: November 30, 2021
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Jose-Andres Salmeron-Garcia, Nels P. Nielson, Heather Brodkin
  • Anti-PD1 antibodies and their use as therapeutics and diagnostics
    Patent number: 11186637
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 30, 2021
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • IL-17 Receptor A antigen binding proteins
    Patent number: 11180564
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 23, 2021
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Antibody therapeutics that bind CD137
    Patent number: 11180568
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 23, 2021
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: John Dixon Gray, Heyue Zhou
  • Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
    Patent number: 11174306
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 16, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • Heterodimer molecule based on CH3 domain, and preparation method and use thereof
    Patent number: 11168149
    Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 9, 2021
    Assignees: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.
    Inventor: Ting Xu
  • Multispecific antibodies, multispecific activatable antibodies and methods of using the same
    Patent number: 11161906
    Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 2, 2021
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, James William West, Sherry Lynn La Porte, Bryan Allen Irving, Daniel Robert Hostetter, Chihunt Wong
  • Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
    Patent number: 11161915
    Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 2, 2021
    Assignee: ZYMEWORKS INC.
    Inventors: Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
  • Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
    Patent number: 11149094
    Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Adam Zwolak
  • Serum albumin-binding immunoglobulin variable domains
    Patent number: 11142569
    Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains, binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 12, 2021
    Assignee: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
    Patent number: 11117936
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Pittsburg—Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller
  • Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
    Patent number: 11111297
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
    Patent number: 11103579
    Abstract: Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 31, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Bryan Barnhart, Maria N. Jure-Kunkel
  • Method for isolation of soluble polypeptides
    Patent number: 11091536
    Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHS and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 17, 2021
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventor: Jamshid Tanha
  • Binding molecules specific for HER3 and uses thereof
    Patent number: 11091554
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Medlmmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto